IQVIA Holdings Inc. $IQV Shares Sold by SVB Wealth LLC

SVB Wealth LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 39.3% in the second quarter, Holdings Channel.com reports. The fund owned 7,434 shares of the medical research company’s stock after selling 4,807 shares during the period. SVB Wealth LLC’s holdings in IQVIA were worth $1,171,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Transce3nd LLC grew its position in IQVIA by 63.4% in the second quarter. Transce3nd LLC now owns 2,603 shares of the medical research company’s stock worth $411,000 after buying an additional 1,010 shares during the last quarter. North Growth Management Ltd. bought a new stake in shares of IQVIA during the 2nd quarter worth $5,224,000. Bank of Nova Scotia grew its holdings in shares of IQVIA by 102.3% in the 2nd quarter. Bank of Nova Scotia now owns 53,969 shares of the medical research company’s stock worth $8,505,000 after acquiring an additional 27,285 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of IQVIA by 3.3% during the second quarter. California Public Employees Retirement System now owns 330,627 shares of the medical research company’s stock valued at $52,104,000 after purchasing an additional 10,602 shares during the last quarter. Finally, Cerity Partners LLC boosted its position in shares of IQVIA by 24.9% in the 2nd quarter. Cerity Partners LLC now owns 158,432 shares of the medical research company’s stock valued at $25,036,000 after purchasing an additional 31,593 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on IQV shares. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Citigroup boosted their target price on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Stifel Nicolaus raised their target price on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, UBS Group upped their price target on IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $241.44.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

Shares of IQV stock opened at $218.20 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $234.29. The stock’s 50-day moving average is $215.90 and its two-hundred day moving average is $188.23. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The firm has a market cap of $37.16 billion, a P/E ratio of 29.93, a PEG ratio of 2.51 and a beta of 1.37.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same period in the previous year, the company earned $2.84 EPS. The firm’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.